Back to Report Store Home

ADHD therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • Published: Jul-2014
  • Report Code: GBIHC337MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Disease Introduction

2.2 Symptoms

2.3 Epidemiology

2.4 Etiology

2.5 Pathophysiology

2.5.1 Diagnosis Rating Scales

2.5.2 DSM-5 Criteria for ADHD

2.5.3 ICD-10 Criteria for Hyperkinetic Disorder

2.6 Treatment

2.6.1 Treatment Algorithm

3 Marketed Products

3.1 Stimulant Drugs

3.1.1 Adderall XR – Shire

3.1.2 Concerta – Janssen Pharmaceuticals

3.1.3 Daytrana – Noven Pharmaceuticals

3.1.4 Focalin XR – Novartis

3.1.5 Ritalin LA – Novartis

3.1.6 Provigil – Teva Pharmaceutical

3.1.7 Quillivant XR– Pfizer Pharmaceuticals

3.1.8 Vyvanse – Shire

3.2 Non-stimulant Drugs

3.2.1 Strattera – Eli Lilly

3.2.2 Intuniv – Shire

3.2.3 Kapvay – Concordia Pharmaceuticals

3.3 Comparative Efficacy and Safety

4 ADHD Pipeline

4.1 Overview

4.2 Mechanisms of Action in the Pipeline

4.3 Clinical Trials

4.3.1 Attrition Rate

4.3.2 Clinical Trial Duration

4.3.3 Clinical Trial Size

4.3.4 Comparative Clinical Trial Metrics Analysis

4.3.5 SHP465 – Shire

4.3.6 NT-0202 – Neos Therapeutics

4.3.7 Edivoxetine – Eli Lilly

4.3.8 NWP09 – Pfizer

4.3.9 NT-0102 – Neos Therapeutics

4.3.10 Metadoxine ER – Alcobra

4.3.11 SPN-812 – Supernus Pharmaceuticals

4.3.12 Dextroamphetamine Transdermal – Noven Pharmaceuticals

4.4 Comparative Efficacy and Safety

5 Market Forecast to 2020

5.1 Global Market

5.2 North America

5.2.1 Treatment Usage Patterns

5.2.2 Annual Cost of Treatment

5.2.3 Market Size

5.3 Leading Five EU Countries (EU5)

5.3.1 Treatment Usage Patterns

5.3.2 Annual Cost of Treatment

5.3.3 Market Size

5.4 Japan

5.4.1 Treatment Usage Patterns

5.4.2 Annual Cost of Treatment

5.4.3 Market Size

5.5 Drivers and Barriers

5.5.1 Drivers

5.5.2 Barriers

6 Deals and Strategic Consolidations

6.1 Overview

6.2 Co-development Deals

7 Appendix

7.1 Market Definition

7.2 Abbreviations

7.3 References

7.4 Research Methodology

7.4.1 Secondary Research

7.4.2 Marketed Product Profiles

7.4.3 Late-Stage Pipeline Candidates

7.4.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products

7.4.5 Product Competitiveness Framework

7.4.6 Pipeline Analysis

7.4.7 Forecasting Model

7.4.8 Deals Data Analysis

7.5 Contact Us

7.6 Disclaimer

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards